

GALERIAS DE IDENTIFICACIÓN CRYSTAL BBL PARA GRAM POSITIVOS (*Bacillus, Enterococcus, Lactococcus, Leuconostoc, Listeria, Micrococcus, Pediococcus, Staphylococcus, Streptococcus...*)

| BBL CRYSTAL™ Gram-Positive Identification Color Chart | | | | | | | | | | | | |
|--|-------|-------|-------|-------|-----|-----|-----|-----|-----|-----|--|--|
| — Negative | 4A | * 4B | * 4C | * 4D | 4E | 4F | 4G | 4H | 4I | 4J | | |
| | | FPH | FTR | FHO | TRE | SUC | ARA | BGL | PHO | URE | | |
| + Positive | FCT | ** 4B | ** 4C | ** 4D | 4E | 4F | 4G | 4H | 4I | 4J | | |
| | | | | | | | | | | | | |
| — Negative | * 2A | * 2B | * 2C | * 2D | 2E | 2F | 2G | 2H | 2I | 2J | | |
| | FGC | FGS | FAR | FGN | LAC | MNT | GLR | PCE | PAM | ESC | | |
| + Positive | ** 2A | ** 2B | ** 2C | ** 2D | 2E | 2F | 2G | 2H | 2I | 2J | | |
| | | | | | | | | | | | | |
| — Negative | * 1A | * 1B | * 1C | * 1D | 1E | 1F | 1G | 1H | 1I | 1J | | |
| | FVA | FPY | FGA | FIS | MAB | MTT | FRU | PLN | PGO | ARG | | |
| + Positive | ** 1A | ** 1B | ** 1C | ** 1D | 1E | 1F | 1G | 1H | 1I | 1J | | |
| | | | | | | | | | | | | |
| * = FLUORESCENCE ≤ FCT ** = FLUORESCENCE > FCT BECTON DICKINSON Refer to package insert for additional information. | | | | | | | | | | | | |

9055221-3 (0697)

BBL Crystal™ Identification Systems

Gram-Positive ID Kit

8809911JAA

2004/04

CLIA COMPLEXITY: HIGH

CDC IDENTIFIER CODES

ANALYTE: 0412

TEST SYSTEM: 07919

U.S. Pat. 5,182,082

U.S. Pat. 5,338,666

See symbol glossary at end of insert.**INTENDED USE**

The **BBL Crystal™** Gram-Positive (GP) Identification (ID) system is a miniaturized identification method employing modified conventional, fluorogenic and chromogenic substrates. It is intended for the identification of aerobic gram-positive bacteria.^{1,2,13,16}

SUMMARY AND EXPLANATION

Micromethods for the biochemical identification of microorganisms were reported as early as 1918.³ Several publications reported on the use of the reagent-impregnated paper discs and micro-tube methods for differentiating enteric bacteria.^{3,4,7,17,19} The interest in miniaturized identification systems led to the introduction of several commercial systems in the late 1960s, and they provided advantages in requiring little storage space, extended shelf life, standardized quality control and ease of use.

In general, many of the tests used in the **BBL Crystal** ID Systems are modifications of classical methods. These include tests for fermentation, oxidation, degradation and hydrolysis of various substrates. In addition, there are chromogen and fluorogen linked substrates, as in the **BBL Crystal** GP ID panel, to detect enzymes that microbes use to metabolize various substrates.^{5,7,8,9,11,12,14,15}

The **BBL Crystal** GP ID kit is comprised of (i) **BBL Crystal** GP ID panel lids, (ii) **BBL Crystal** bases and (iii) **BBL Crystal** ANR, GP, RGP, N/H ID Inoculum Fluid (IF) tubes. The lid contains 29 dehydrated substrates and a fluorescence control on tips of plastic prongs. The base has 30 reaction wells. Test inoculum is prepared with the inoculum fluid and is used to fill all 30 wells in the base. When the lid is aligned with the base and snapped in place, the test inoculum rehydrates the dried substrates and initiates test reactions.

Following an incubation period, the wells are examined for color changes or presence of fluorescence that result from metabolic activities of the microorganisms. The resulting pattern of the 29 reactions is converted into a ten-digit profile number that is used as the basis for identification.¹⁸ Biochemical and enzymatic reaction patterns for the 29 **BBL Crystal** GP ID substrates for a wide variety of microorganisms are stored in the **BBL Crystal** GP ID data base. Identification is derived from a comparative analysis of the reaction pattern of the test isolate to those held in the database. A complete list of taxa that comprises the current database is provided in **Table 1** (see pg. 7).

PRINCIPLES OF THE PROCEDURE

The **BBL Crystal** GP ID panels contain 29 dried biochemical and enzymatic substrates. A bacterial suspension in the inoculum fluid is used for rehydration of the substrates. The tests used in the system are based on microbial utilization and degradation of specific substrates detected by various indicator systems. Enzymatic hydrolysis of fluorogenic substrates containing coumarin derivatives of 4-methylumbelliferone (4MU) or 7-amino-4-methylcoumarin (7-AMC), results in increased fluorescence that is easily detected visually with a UV light source.^{11,12,14,15} Chromogenic substrates upon hydrolysis produce color changes that can be detected visually. In addition, there are tests that detect the ability of an organism to hydrolyze, degrade, reduce or otherwise utilize a substrate in the **BBL Crystal** ID Systems.

Reactions employed by various substrates and a brief explanation of the principles employed in the system are described in **Table 2** (see pg. 8). Panel location in referred tables indicates the row and column where the well is located (example: 1J refers to Row 1 in column J).

REAGENTS

The **BBL Crystal** GP ID panel contains 29 enzymatic and biochemical substrates. Refer to **Table 3** (see pg. 9) for a list of active ingredients.

Warnings and Precautions:

For *in vitro* Diagnostic Use.

After review by the U.S. Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) under CLIA '88, this product has been identified as high complexity. The CDC Analyte Identifier Code is 0412; the CDC Test System Identifier Code is 07919.

After use, all infectious materials including plates, cotton swabs, inoculum fluid tubes, and panels must be autoclaved prior to disposal or incineration.

STORAGE AND HANDLING/SHELF LIFE

Lids: BBL Crystal GP lids are individually packaged and must be stored unopened in a refrigerator at 2–8°C. DO NOT FREEZE. Visually inspect the package for holes or cracks in the foil package. Do not use if the packaging appears to be damaged. Lids in the original packaging, if stored as recommended, will retain expected reactivity until the date of expiration.

Bases: Bases are packaged in two sets of ten, in BBL Crystal incubation trays. The bases are stacked facing down to minimize air contamination. Store in a dust-free environment at 2–30°C, until ready to use. Store unused bases in the tray, in plastic bag. Empty trays should be used to incubate inoculated panels.

Inoculum Fluid: BBL Crystal ANR, GP, RGP, N/H ID Inoculum Fluid (IF) is packaged in two sets of ten tubes. Visually inspect the tubes for cracks, leaks, etc. Do not use if there appears to be a leak, tube or cap damage or visual evidence of contamination (i.e., haziness, turbidity). Store tubes at 2–25°C. Expiration dating is shown on the tube label. Only ANR, GP, RGP, N/H Inoculum Fluid should be used with BBL Crystal GP ID panels.

On receipt, store the BBL Crystal GP ID kit at 2–8°C. Once opened, only the lids need to be stored at 2–8°C. The remaining components of the kit may be stored at 2–25°C. If the kit or any of the components are stored refrigerated, each should be brought to room temperature prior to use.

SPECIMEN COLLECTION AND PROCESSING

BBL Crystal ID Systems are not for use directly with clinical specimens. Use isolates from media such as Trypticase™ Soy Agar with 5% Sheep Blood (TSA II) or Columbia Agar with 5% Sheep Blood (Columbia Blood Agar). Use of selective media such as Phenylethyl Alcohol Agar with 5% Sheep Blood (PEA) or Columbia CNA Agar with 5% Sheep Blood (CNA) is also acceptable. Media containing esculin should not be used. The test isolate must be a pure culture, no more than 18–24 h old for most genera; for some slow growing organisms up to 48 h may be acceptable. When swabs are utilized, only cotton-tipped applicators should be used to prepare the inoculum suspensions. Some polyester swabs may cause problems with inoculation of the panels. (See "Limitations of the Procedure").

The incubator used should be humidified to prevent evaporation of fluid from the wells during incubation. The recommended humidity level is 40–60%. The usefulness of BBL Crystal ID Systems or any other diagnostic procedure performed on clinical specimens is directly influenced by the quality of the specimens themselves. It is strongly recommended that laboratories employ methods discussed in the *Manual of Clinical Microbiology* for specimen collection, transport and inoculation onto primary isolation media.^{1,16}

TEST PROCEDURE

Materials Provided: BBL Crystal GP ID Kit –

20 BBL Crystal GP ID Panel Lids,

20 BBL Crystal Bases,

20 BBL Crystal ANR, GP, RGP, N/H ID IF Tubes. Each tube has approximately 2.3 ± 0.15 mL of Inoculum Fluid containing: KCl 7.5 g, CaCl₂ 0.5 g, Tricine N-[2-Hydroxy-1, 1-bis (hydroxymethyl)methyl] glycine 0.895 g, purified water to 1000 mL,

2 incubation trays,


1 BBL Crystal GP ID Color Reaction Chart and Results Pad.

Materials Required But Not Provided: Sterile cotton swabs (*do not use polyester swabs*), incubator (35 – 37°C non-CO₂ (40–60% humidity), McFarland No. 0.5 standard, BBL Crystal Panel Viewer, BBL Crystal ID System Electronic Codebook or BBL Crystal Gram-Positive Manual Codebook, and appropriate culture media.

Also required are the necessary equipment and labware used for preparation, storage and handling of clinical specimens.

Test Procedure: BBL Crystal GP ID System requires a Gram stain.


1. Remove lids from pouch. Discard desiccant. Once removed from the pouch, covered lids should be used within 1 h. Do not use the panel if there is no desiccant in the pouch.
2. Take an inoculum fluid tube and label with patient's specimen number. Using aseptic technique, pick colonies of the same morphology with the tip of a sterile cotton swab (*do not use a polyester swab*) or a wooden applicator stick from one of the recommended media (see section under "Specimen Collection and Processing").
3. Suspend colonies in a tube of BBL Crystal ANR, GP, RGP, N/H ID Inoculum Fluid.
4. Recap tube and vortex for approximately 10–15 s. The turbidity should be equivalent to a McFarland No. 0.5 standard. If the inoculum suspension concentration is in excess of the recommended McFarland standard, one of the following steps is recommended:
 - a. Use a fresh tube of inoculum fluid to prepare a new inoculum suspension equivalent to a McFarland No. 0.5 standard.
 - b. If additional colonies are unavailable for preparation of a new inoculum suspension, using aseptic techniques, dilute the inoculum by adding the minimum required volume (not to exceed 1.0 mL) of 0.85% sterile saline or inoculum fluid to bring down the turbidity equivalent to a McFarland No. 0.5 standard. Remove the excess amount added to the tube with a sterile pipet so that the final volume of inoculum fluid is approximately equivalent to that of the original volume in the tube (2.3 ± 0.15 mL). Failure to make this adjustment in volume will result in spilling of the inoculum suspension over the black portion of the base rendering the panel unusable.




5. Take a base, and mark the patient's specimen number on the side wall.
6. Pour entire contents of the inoculum fluid tube into target area of the base.




7. Hold base in both hands and roll inoculum gently along the tracks until all of the wells are filled. Roll back any excess fluid to the target area and place the base on a bench top.



8. Align the lid so that the labeled end of the lid is on top of the target area of the base.




9. Push down until a slight resistance is felt. Place thumb on edge of lid towards middle of panel on each side and push downwards simultaneously until the lid snaps into place (listen for two "clicks").




Purity Plate: Using a sterile loop, recover a small drop from the inoculum fluid tube either before or after inoculating the base and inoculate an agar slant or plate (any appropriate medium) for purity check. Discard inoculum fluid tube and cap in a biohazard disposal container. Incubate the slant or plate for 24–48 h at 35–37°C under appropriate conditions. The purity plate or slant may also be used for any supplementary tests or serology, if required.

Incubation: Place inoculated panels in incubation trays. Ten panels can fit in one tray (5 rows of 2 panels). All panels should be incubated **face down** (larger windows facing up; label facing down) in a non-CO₂ incubator with 40–60% **humidity**. Trays should not be stacked more than two high during incubation. The incubation time for panels is 18–24 h at 35–37°C. If panels are incubated for 24 h, they should be read within 30 min after removing from incubator.



Reading: After the recommended period of incubation, remove the panels from the incubator. All panels should be read **face down** (larger windows up; label facing down) using the **BBL Crystal Panel Viewer**. Refer to the color reaction chart and/or **Table 3** (see pg. 9) for an interpretation of the reactions. Use the results pad to record reactions. Alternatively, the **BBL Crystal AutoReader** may be used to read the panels.

- a. Read columns E thru J first, using the regular (white) light source.
- b. Read columns A thru D (fluorescent substrates) using the UV light source in the panel viewer. A fluorescent substrate well is considered positive *only* if the intensity of the fluorescence observed in the well is *greater* than the Negative Control well (4A).



Calculation of BBL Crystal Profile Number: Each test result (except 4A, which is used as a fluorescence negative control) scored positive is given a value of 4, 2, or 1, corresponding to the row where the test is located. A value

of 0 (zero) is given to any negative result. The values resulting from each positive reaction in each column are then added together. A 10-digit number is generated; this is the profile number.

| Example: | A | B | C | D | E | F | G | H | I | J |
|----------|---|---|---|---|---|---|---|---|---|---|
| 4 | * | + | - | - | + | + | + | - | + | - |
| 2 | - | + | + | + | - | + | - | + | + | - |
| 1 | + | - | + | - | + | - | - | + | + | - |
| Profile | 1 | 6 | 3 | 2 | 5 | 6 | 4 | 3 | 7 | 0 |

*(4A) = fluorescent negative control

The resulting profile number and cell morphology, if known, should be entered on a PC in which the **BBL Crystal** Mind Software has been installed to obtain the identification. If using the **BBL Crystal** AutoReader, organisms are automatically identified by the PC. A manual codebook is also available. If a PC is not available contact BD Technical Services for assistance with the identification.

User Quality Control: Quality control testing is recommended for each lot of panels as follows –

1. Inoculate a panel with *Streptococcus pyogenes* ATCC™ 19615 per recommended procedure (refer to "Test Procedure").
2. Incubate panel for 18–20 h at 35–37°C.
3. Read panel with the panel viewer and color reaction chart; record reactions using the results pad. Alternatively, read the panel on the **BBL Crystal** AutoReader.
4. Compare recorded reactions with those listed in **Table 4** (see pg. 10). If discrepant results are obtained, confirm purity of quality control strain before contacting BD Technical Services.

Expected test results for additional quality control test strains are listed in **Table 5** (see pg. 10).

Quality control requirements must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory's standard Quality Control procedures. It is recommended that the user refer to pertinent NCCLS guidance and CLIA regulations for appropriate Quality Control practices.

LIMITATIONS OF THE PROCEDURE

The **BBL Crystal** GP ID System is designed for the taxa provided. Taxa other than those listed in **Table 1** are not intended for use in this system.

The **BBL Crystal** GP ID System database includes some species that are rarely isolated from human clinical specimens and were not encountered in the clinical studies of this product. It also includes some species that were encountered less than 10 times in the clinical studies. Refer to **Table 1** (see pg. 7) for a breakdown of the number of strains per species tested in clinical trials. The laboratorian should determine if additional testing is required to confirm identity of those species for which performance has not been established (i.e., those species where less than 10 isolates were evaluated in the clinical trials for this product).

The **BBL Crystal** GP ID database was developed with **BBL™** brand media. Reactivity of some substrates in miniaturized identification systems may be dependent upon the source media used in inoculum preparations. We recommend the use of the following media for use with the **BBL Crystal** GP ID System: TSA II and Columbia Blood Agar. Use of selective media, such as PEA or CNA is also acceptable. Media containing esculin should not be used.

BBL Crystal Identification Systems use a modified microenvironment; therefore, expected values for its individual tests may differ from information previously established with conventional test reactions. The accuracy of the **BBL Crystal** GP ID System is based on statistical use of specially designed tests and an exclusive database.

While **BBL Crystal** GP ID System aids in microbial differentiation, it should be recognized that minor variations may exist in strains within species. Use of panels and interpretation of results require a competent microbiologist. The final identification of the isolate should take into consideration the source of the specimen, aerotolerance, cell morphology, colonial characteristics on various media as well as metabolic end products as determined by gas-liquid chromatography, when warranted.

Only cotton-tipped applicator swabs should be used to prepare the inoculum suspension as some polyester swabs may cause the inoculum fluid to become viscous. This may result in insufficient inoculum fluid to fill the wells. Covered lids once removed from the sealed pouches must be used within 1 h to ensure adequate performance.

The incubator where panels are placed should be humidified to prevent evaporation of inoculum fluid from the wells during incubation. The recommended humidity level is 40–60%.

The panels, after inoculation, should only be incubated face down (larger windows facing up; label facing down) to maximize the effectiveness of substrates.

If the **BBL Crystal** test profile yields a "No identification" result and culture purity has been confirmed, then it is likely that (i) the test isolate is producing *atypical BBL Crystal reactions* (which may also be caused by procedural errors), (ii) the test species is not part of the intended taxa or (iii) the system is unable to identify the test isolate with the required level of confidence. Conventional test methods are recommended when user error has been ruled out.

EXPECTED VALUES

The expected substrate reactions for the species of organisms most frequently encountered in the clinical study of **BBL Crystal** GP ID System are shown in **Table 6** (see pg. 11). The provided percentages were generated from reactions given by the organisms used in generating the database. **Table 1** (see pg. 7) shows all the taxa tested during database generation.

PERFORMANCE CHARACTERISTICS

Reproducibility: In an external study involving four clinical laboratories, (total of four evaluations), the reproducibility of BBL Crystal GP ID substrates' (29) reactions was studied by replicate testing. The reproducibility of the individual substrate reactions ranged from 79.2%–100%. The overall reproducibility of BBL Crystal GP ID panel was determined to be 96.7%.²⁰

Accuracy of Identification: The performance of BBL Crystal GP ID System was compared to currently available commercial systems using clinical isolates and stock cultures. A total of four studies were conducted in four independent laboratories. Fresh, routine isolates arriving in the clinical laboratory, as well as previously identified isolates of the clinical trial sites' choice, were utilized to establish performance characteristics.

Out of 735 total isolates tested from the four studies using BBL Crystal GP Identification System, 623 (84.8%) were correctly identified without the use of supplement tests, and 668 (90.9%) were correctly identified when supplemental tests were included. A total of 56 (7.6%) isolates were incorrectly identified, and a message of "No Identification" was obtained for 11 (1.5%) isolates.²⁰ Table 7 (see pg. 12) shows the accuracy of identification for the species most frequently encountered (i.e., 10 or more isolates) in the clinical trial as well as for the remaining group of species where less than 10 isolates were tested.

AVAILABILITY

| Cat. No. | Description | Cat. No. | Description |
|----------|---|----------|--|
| 245240 | BBL Crystal™ Gram-Positive ID Kit, containing 20 each: BBL Crystal GP ID Panel Lids, BBL Crystal Bases and BBL Crystal ANR, GP, RGP, N/H ID Inoculum Fluid. | 245300 | BBL Crystal™ AutoReader |
| 245038 | BBL Crystal™ ANR, GP, RGP, N/H ID Inoculum Fluid, ctn. of 10. | 221165 | BBL™ Columbia Agar with 5% Sheep Blood, pkg. of 20. |
| 245031 | BBL Crystal™ Panel Viewer, Domestic model, 110 V, 60 Hz. | 221263 | BBL™ Columbia Agar with 5% Sheep Blood, ctn. of 100. |
| 245032 | BBL Crystal™ Panel Viewer, European model, 220 V, 50 Hz. | 221352 | BBL™ Columbia CNA Agar with 5% Sheep Blood, pkg. of 20. |
| 245033 | BBL Crystal™ Panel Viewer, Japanese model, 100 V, 50/60 Hz. | 221353 | BBL™ Columbia CNA Agar with 5% Sheep Blood, ctn. of 100. |
| 245034 | BBL Crystal™ Panel Viewer, Longwave UV Tube. | 221179 | BBL™ Phenylethyl Alcohol Agar with 5% Sheep Blood, pkg. of 20. |
| 245036 | BBL Crystal™ Panel Viewer, White Light Tube. | 221277 | BBL™ Phenylethyl Alcohol Agar with 5% Sheep Blood, ctn. of 100. |
| 245037 | BBL Crystal™ Identification Systems Gram-Positive Manual Codebook. | 221239 | BBL™ Trypticase™ Soy Agar with 5% Sheep Blood (TSA II), pkg. of 20. |
| 441010 | BBL Crystal™ Mind Software | 221261 | BBL™ Trypticase™ Soy Agar with 5% Sheep Blood (TSA II), ctn. of 100. |
| | | 212539 | BBL™ Gram Stain Kit, pkg. of 4 x 250 mL bottles. |

REFERENCES

- Balows, A., W.J. Hausler, Jr., K.L. Herrmann, H.D. Isenberg, and H.J. Shadomy (ed.). 1991. Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
- Baron, E.J., L.R. Peterson, and S.M. Finegold. 1994. Bailey and Scott's diagnostic microbiology, 9th ed. Mosby-Year Book, Inc., St. Louis.
- Bronfenbrenner, J., and M.J. Schlesinger. 1918. A rapid method for the identification of bacteria fermenting carbohydrates. Am. J. Public Health. 8:922-923.
- Cowan, S.T., and K.J. Steel. 1974. Manual for the identification of medical bacteria. 2nd ed. Cambridge University Press, Cambridge.
- Edberg, S.C., and C.M. Kontnick. 1986. Comparison of β -glucuronidase-based substrate systems for identification of *Escherichia coli*. J. Clin. Microbiol. 24:368-371.
- Ferguson, W.W., and A.E. Hook. 1943. Urease activity of *Proteus* and *Salmonella* organisms. J. Lab. Clin. Med. 28:1715-1720.
- Hartman, P.A. 1968. Miniaturized microbiological methods. Academic Press, New York.
- Kampfer, P., O. Rauhoff, and W. Dott. 1991. Glycosidase profiles of members of the family Enterobacteriaceae. J. Clin. Microbiol. 29:2877-2879.
- Killian, M., and P. Bulow. 1976. Rapid diagnosis of Enterobacteriaceae 1: detection of bacterial glycosidases. Acta Pathol. Microbiol. Scand. Sect. B. 84:245-251.
- MacFaddin, J.F. 1980. Biochemical tests for identification of medical bacteria, 2nd ed. Williams & Wilkins, Baltimore.
- Maddocks, J.L., and M. Greenan. 1975. Rapid method for identifying bacterial enzymes. J. Clin. Pathol. 28:686-687.
- Manafi, M., W. Kneifel, and S. Bascomb. 1991. Fluorogenic and chromogenic substrates used in bacterial diagnostics. Microbiol. Rev. 55:335-348.
- Mandell, G.L., R.G. Douglas, Jr. and J.E. Bennett. 1990. Principles and practice of infectious diseases, 3rd ed. Churchill Livingstone Inc., New York.
- Mangels, J., I. Edvalson, and M. Cox. 1993. Rapid Identification of *Bacteroides fragilis* group organisms with the use of 4-methylumbelliferone derivative substrates. Clin. Infect. Dis. 16(54):5319-5321.

15. Moncla, B.J., P. Braham, L.K. Rabe, and S.L. Hiller. 1991. Rapid presumptive identification of black-pigmented gram-negative anaerobic bacteria by using 4-methylumbelliferone derivatives. *J. Clin. Microbiol.* 29:1955-1958.
16. Murray, P.R., E.J. Baron, M.A. Pfaller, F.C. Tenover, and R.H. Tenover (ed.). 1995. *Manual of clinical microbiology*, 6th ed. American Society for Microbiology, Washington, D.C.
17. Sanders, A.C., J.E. Faber, and T.M. Cook. 1957. A rapid method for the characterization of enteric pathogen using paper discs. *Appl. Microbiol.* 5:36-40.
18. Sneath, P.H.A. 1957. The application of computers to taxonomy. *J. Gen. Microbiol.* 17:201-221.
19. Soto, O.B. 1949. Fermentation reactions with dried paper discs containing carbohydrate and indicator. *Puerto Rican J. Public Health. Trop. Med.* 25:96-100.
20. Data on file at BD Diagnostics.

Key: Table 1

KEY: * = These taxa have fewer than 10 unique **BBL Crystal** profiles in the current database.
("x") = Number of isolates (i.e., "x") encountered in the clinical trial. If no number in parenthesis is shown after an organism name or group description, these species were not encountered in the clinical trial.

Note #1: There were 14 additional isolates encountered in the clinical trial that are not shown above. Five (5) (i.e., 4 *Staphylococcus* species and 1 *Enterococcus*) were identified only to the genus level by the reference system against which **BBL Crystal** GP was compared, although **BBL Crystal** GP identified these organisms to the species level. Nine (9) were identified by the reference system, but were not included in the **BBL Crystal** GP database taxa.

Note #2: The organisms shown in bold face type were encountered 10 or more times in the clinical study for this product.

Note #3: The organisms not shown in bold face type are either species which are rarely isolated from human clinical specimens or species that were infrequently (less than 10) encountered in the clinical study for this product. The laboratorian should determine if additional testing is required to confirm their identity.

Table 1**Taxa in BBL Crystal™ GP ID System**

| | | | |
|--|--|--|---|
| <i>Actinomyces pyogenes</i> | <i>Enterococcus durans</i> (2) | <i>Paenibacillus macerans</i> | <i>Streptococcus agalactiae</i> (54) |
| <i>Aerococcus</i> species (includes <i>A. urinae</i> and <i>A. viridans</i>) | <i>Enterococcus faecalis</i> (78) | <i>Pediococcus damnosus</i> | <i>Streptococcus anginosus</i> (1) |
| <i>Aerococcus urinae</i> | <i>Enterococcus faecium</i> (33) | <i>Pediococcus parvulus</i> | <i>Streptococcus bovis</i> (includes <i>S. bovis</i> I and <i>S. bovis</i> II) (10) |
| <i>Aerococcus viridans</i> | <i>Enterococcus hirae</i> | <i>Pediococcus pentosaceus</i> | <i>Streptococcus constellatus</i> (1) |
| <i>Alloibacterium otitidis</i> * | <i>Enterococcus raffinosus</i> (3) | <i>Pediococcus</i> species (includes <i>P. damnosus</i> , <i>P. parvulus</i> and <i>P. pentosaceus</i>) | <i>Streptococcus cricetus</i> * |
| <i>Arcanobacterium</i> <i>haemolyticum</i> *(2) | <i>Enterococcus solitarius</i> | <i>Rhodococcus equi</i> | <i>Streptococcus crista</i> |
| <i>Bacillus brevis</i> (1) | <i>Erysipelothrix rhusiopathiae</i> | <i>Rothia dentocariosa</i> * (1) | <i>Streptococcus equi</i> (includes <i>S. equi</i> subsp <i>equi</i> and <i>S. equi</i> subsp <i>zooepidemicus</i>) (1) |
| <i>Bacillus cereus</i> (2) | <i>Gardnerella vaginalis</i> | <i>Staphylococcus aureus</i> (88) | <i>Streptococcus equi</i> subsp <i>equi</i> (2) |
| <i>Bacillus circulans</i> | <i>Gemella haemolysans</i> | <i>Staphylococcus auricularis</i> (2) | <i>Streptococcus equi</i> subsp <i>zooepidemicus</i> |
| <i>Bacillus coagulans</i> | <i>Gemella morbillorum</i> | <i>Staphylococcus capitis</i> (includes <i>S. capitis</i> subsp <i>capitis</i> and <i>S. capitis</i> subsp <i>ureolyticus</i>) (13) | <i>Streptococcus equinus</i> |
| <i>Bacillus licheniformis</i> (1) | <i>Gemella</i> species (includes <i>G. haemolysans</i> and <i>G. morbillorum</i>) | <i>Staphylococcus caprae</i> | <i>Streptococcus gordonii</i> |
| <i>Bacillus megaterium</i> | <i>Globicatella sanguis</i> (3) | <i>Staphylococcus carnosus</i> | <i>Streptococcus</i> Group C/G (11) |
| <i>Bacillus pumilus</i> | <i>Helcococcus kunzii</i> | <i>Staphylococcus cohnii</i> (includes <i>S. cohnii</i> subsp <i>cohnii</i> and <i>S. cohnii</i> subsp <i>urealyticum</i>) (1) | <i>Streptococcus intermedius</i> |
| <i>Bacillus</i> species (includes <i>B. brevis</i> , <i>B. circulans</i> , <i>B. coagulans</i> , <i>B. licheniformis</i> , <i>B. megaterium</i> , <i>B. pumilus</i> and <i>B. sphaericus</i> , <i>P. alvei</i> , <i>P. macerans</i>) (9) | <i>Lactococcus lactis</i> subsp <i>cremoris</i> | <i>Staphylococcus cohnii</i> subsp <i>cohnii</i> | <i>Streptococcus milleri</i> group (includes <i>S. anginosus</i>, <i>S. constellatus</i> and <i>S. intermedius</i>) (20) |
| <i>Bacillus sphaericus</i> | <i>Lactococcus lactis</i> subsp <i>lactis</i> | <i>Staphylococcus cohnii</i> subsp <i>urealyticum</i> | <i>Streptococcus mitis</i> (4) |
| <i>Bacillus subtilis</i> (1) | <i>Lactococcus raffinolactis</i> | <i>Staphylococcus</i> <i>epidermidis</i> (88) | <i>Streptococcus mitis</i> group (includes <i>S. mitis</i> and <i>S. oralis</i>) (20) |
| <i>Corynebacterium aquaticum</i> | <i>Lactococcus</i> species (includes <i>L. lactis</i> subsp <i>cremoris</i> , <i>L. lactis</i> subsp <i>hordniae</i> , <i>L. lactis</i> subsp <i>lactis</i> and <i>L. raffinolactis</i>) | <i>Staphylococcus equorum</i> | <i>Streptococcus mutans</i> |
| <i>Corynebacterium bovis</i> | <i>Leuconostoc citreum</i> | <i>Staphylococcus felis</i> | <i>Streptococcus mutans</i> group (includes <i>S. cricetus</i> , <i>S. mutans</i> and <i>S. sobrinus</i>) (2) |
| <i>Corynebacterium diphtheriae</i> (includes <i>C. diphtheriae</i> subsp <i>gravis</i> , <i>C. diphtheriae</i> subsp <i>mitis</i> and <i>C. diphtheriae</i> subsp <i>intermedius</i>) | <i>Leuconostoc lactis</i> (1) | <i>Staphylococcus gallinarum</i> | <i>Streptococcus oralis</i> |
| <i>Corynebacterium genitalium</i> | <i>Leuconostoc mesenteroides</i> subsp <i>mesenteroides</i> | <i>Staphylococcus</i> <i>haemolyticus</i> (23) | <i>Streptococcus parasanguis</i> (1) |
| <i>Corynebacterium jeikeium</i> (7) | <i>Leuconostoc pseudomesenteroides</i> | <i>Staphylococcus</i> <i>hominis</i> (17) | <i>Streptococcus</i> <i>pneumoniae</i> (54) |
| <i>Corynebacterium kutscheri</i> | <i>Leuconostoc</i> species (includes <i>L. citreum</i> , <i>L. lactis</i> , <i>L. mesenteroides</i> subsp <i>mesenteroides</i> and <i>L. pseudomesenteroides</i>) | <i>Staphylococcus intermedius</i> | <i>Streptococcus parvulus</i> |
| <i>Corynebacterium propinquum</i> (1) | <i>Listeria grayi</i> * | <i>Staphylococcus kloeosii</i> (2) | <i>Streptococcus</i> <i>pyogenes</i> (50) |
| <i>Corynebacterium pseudodiphtheriticum</i> (2) | <i>Listeria ivanovii</i> subsp <i>ivanovii</i> | <i>Staphylococcus lentus</i> | <i>Streptococcus salivarius</i> (3) |
| <i>Corynebacterium pseudogenitalium</i> | <i>Listeria monocytogenes</i> (3) | <i>Staphylococcus lugdunensis</i> (3) | <i>Streptococcus salivarius</i> group (includes <i>S. salivarius</i> and <i>S. vestibularis</i>) (4) |
| <i>Corynebacterium pseudotuberculosis</i> (2) | <i>Listeria murrayi</i> | <i>Staphylococcus pasteuri</i> *(1) | <i>Streptococcus sanguis</i> (2) |
| <i>Corynebacterium renale</i> group | <i>Micrococcus kristinae</i> | <i>Staphylococcus saccharolyticus</i> (6) | <i>Streptococcus sanguis</i> group (includes <i>S. crista</i> , <i>S. gordonii</i> , <i>S. parasanguis</i> and <i>S. sanguis</i>) |
| <i>Corynebacterium</i> species (includes <i>C. aquaticum</i>, <i>C. bovis</i>, <i>C. kutscheri</i>, <i>C. propinquum</i>, <i>C. pseudodiphtheriticum</i>, <i>C. pseudotuberculosis</i>, <i>C. renale</i> group, <i>C. striatum</i> and <i>C. ulcerans</i>) (29) | <i>Micrococcus luteus</i> | <i>Staphylococcus saprophyticus</i> | <i>Streptococcus sobrinus</i> |
| <i>Corynebacterium striatum</i> (6) | <i>Micrococcus lylae</i> | <i>Staphylococcus schleiferi</i> (includes <i>S. schleiferi</i> subsp <i>coagulans</i> and <i>S. schleiferi</i> subsp <i>schleiferi</i>) | <i>Streptococcus uberis</i> |
| <i>Corynebacterium ulcerans</i> | <i>Micrococcus roseus</i> | <i>Staphylococcus sciuri</i> | <i>Streptococcus vestibularis</i> |
| <i>Enterococcus avium</i> (3) | <i>Micrococcus sedentarius</i> | <i>Staphylococcus similans</i> (3) | <i>Turicella otitidis</i> * |
| <i>Enterococcus</i> <i>casseliflavus</i>gallinarum (14) | <i>Micrococcus</i> species (includes <i>M. kristinae</i>, <i>M. luteus</i>, <i>M. lylae</i>, <i>M. roseus</i> and <i>M. sedentarius</i>) (10) | <i>Staphylococcus vitulus</i> | |
| | <i>Oerskovia</i> species (includes <i>O. turbata</i> and <i>O. xanthineolytica</i>) | <i>Staphylococcus warneri</i> (6) | |
| | <i>Paenibacillus alvei</i> | <i>Staphylococcus xylosus</i> (1) | |
| | | <i>Stomatococcus mucilaginosus</i> (6) | |
| | | <i>Streptococcus acidominimus</i> | |

Table 2
Principles of Tests Employed in the BBLCrystal™ GP ID System

| Panel Location | Test Feature | Code | Principle (Reference) |
|----------------|---|------|--|
| 4A | Fluorescent negative control | FCT | Control to standardize fluorescent substrate results. |
| 2A | 4MU- β -D-glucoside | FGC | Enzymatic hydrolysis of the amide or glycosidic bond results in the release of a fluorescent coumarin derivative. ^{5,8,11,12,14,15} |
| 1A | L-valine-AMC | FVA | |
| 4B | L-phenylalanine-AMC | FPH | |
| 2B | 4MU- α -D-glucoside | FGS | |
| 1B | L-pyroglutamic acid-AMC | FPY | |
| 4C | L-tryptophan-AMC | FTR | |
| 2C | L-arginine-AMC | FAR | |
| 1C | 4MU-N-acetyl- β -D-glucosaminide | FGA | |
| 4D | 4MU-phosphate | FHO | |
| 2D | 4MU- β -D-glucuronide | FGN | |
| 1D | L-isoleucine-AMC | FIS | |
| 4E | Trehalose | TRE | Utilization of carbohydrate results in lower pH and change in indicator (Phenol red). ^{1,2,3,4,7,16} |
| 2E | Lactose | LAC | |
| 1E | Methyl- α & β -glucoside | MAB | |
| 4F | Sucrose | SUC | |
| 2F | Mannitol | MNT | |
| 1F | Maltotriose | MTT | |
| 4G | Arabinose | ARA | |
| 2G | Glycerol | GLR | Enzymatic hydrolysis of the colorless aryl substituted glycoside releases yellow p-nitrophenol. ^{5,9,12} |
| 1G | Fructose | FRU | |
| 4H | p-nitrophenyl- β -D-glucoside | BGL | |
| 2H | p-nitrophenyl- β -D-cellobioside | PCE | Enzymatic hydrolysis of the colorless amide substrate releases yellow p-nitroaniline. ^{5,9,12} |
| 1H | Proline & Leucine-p-nitroanilide | PLN | |
| 4I | p-nitrophenyl-phosphate | PHO | Enzymatic hydrolysis of the colorless aryl substituted glycoside releases yellow p-nitrophenol. ^{5,9,12} |
| 2I | p-nitrophenyl- α -D-maltoside | PAM | |
| 1I | o-nitrophenyl- β -D-galactoside (ONPG) & p-nitrophenyl- α -D-galactoside | PGO | Hydrolysis of urea and the resulting ammonia change the pH indicator color (Bromthymol blue). ^{2,6,10} |
| 4J | Urea | URE | |
| 2J | Esculin | ESC | |
| 1J | Arginine | ARG | Utilization of arginine results in pH rise and change in the color of the indicator (Bromcresol purple). ² |

Table 3

Reagents used in the BBL Crystal™ GP ID System

| Panel Location | Substrate | Code | Pos. | Neg. | Active Ingredients | Approx. Amt. (g/L) |
|----------------|----------------------------------|------|--------------------------------|--------------------------------|----------------------------------|--------------------|
| 4A | Fluorescent negative control | FCT | n/a | n/a | Fluorescent coumarin derivative | ≤1 |
| 2A | 4MU-β-D-glucoside | FGC | blue fluorescence >FCT well | blue fluorescence ≤FCT well | 4MU-β-D-glucoside | ≤1 |
| 1A | L-valine-AMC | FVA | blue fluorescence >FCT well | blue fluorescence ≤FCT well | L-valine-AMC | ≤1 |
| 4B | L-phenylalanine-AMC | FPH | blue fluorescence >FCT well | blue fluorescence ≤FCT well | L-phenylalanine-AMC | ≤1 |
| 2B | 4MU-α-D-glucoside | FGS | blue fluorescence >FCT well | blue fluorescence ≤FCT well | 4MU-α-D-glucoside | ≤1 |
| 1B | L-pyroglutamic acid-AMC | FPY | blue fluorescence >FCT well | blue fluorescence ≤FCT well | L-pyroglutamic acid-AMC | ≤1 |
| 4C | L-tryptophan-AMC | FTR | blue fluorescence >FCT well | blue fluorescence ≤FCT well | L-tryptophan-AMC | ≤1 |
| 2C | L-arginine-AMC | FAR | blue fluorescence >FCT well | blue fluorescence ≤FCT well | L-arginine-AMC | ≤1 |
| 1C | 4MU-N-acetyl-β-D-glucosaminide | FGA | blue fluorescence >FCT well | blue fluorescence ≤FCT well | 4MU-N-acetyl-β-D-glucosaminide | ≤1 |
| 4D | 4MU-phosphate | FHO | blue fluorescence >FCT well | blue fluorescence ≤FCT well | 4MU-phosphate | ≤1 |
| 2D | 4MU-β-D-glucuronide | FGN | blue fluorescence >FCT well | blue fluorescence ≤FCT well | 4MU-β-D-glucuronide | ≤1 |
| 1D | L-isoleucine-AMC | FIS | blue fluorescence >FCT well | blue fluorescence ≤FCT well | L-isoleucine-AMC | ≤1 |
| 4E | Trehalose | TRE | Gold/Yellow | Orange/Red | Trehalose | ≤300 |
| 2E | Lactose | LAC | Gold/Yellow | Orange/Red | Lactose | ≤300 |
| 1E | Methyl-α & β-glucoside | MAB | Gold/Yellow | Orange/Red | Methyl-α & β-glucoside | ≤300 |
| 4F | Sucrose | SUC | Gold/Yellow | Orange/Red | Sucrose | ≤300 |
| 2F | Mannitol | MNT | Gold/Yellow | Orange/Red | Mannitol | ≤300 |
| 1F | Maltotriose | MTT | Gold/Yellow | Orange/Red | Maltotriose | ≤300 |
| 4G | Arabinose | ARA | Gold/Yellow | Orange/Red | Arabinose | ≤300 |
| 2G | Glycerol | GLR | Gold/Yellow | Orange/Red | Glycerol | ≤300 |
| 1G | Fructose | FRU | Gold/Yellow | Orange/Red | Fructose | ≤300 |
| 4H | p-n-p-β-D-glucoside | BGL | Yellow | Colorless | p-n-p-β-D-glucoside | ≤10 |
| 2H | p-n-p-β-D-cellobioside | PCE | Yellow | Colorless | p-n-p-β-D-cellobioside | ≤10 |
| 1H | Proline & Leucine-p-nitroanilide | PLN | Yellow | Colorless | Proline & Leucine-p-nitroanilide | ≤10 |
| 4I | p-n-p-phosphate | PHO | Yellow | Colorless | p-n-p-phosphate | ≤10 |
| 2I | p-n-p-α-D-maltoside | PAM | Yellow | Colorless | p-n-p-α-D-maltoside | ≤10 |
| 1I | ONPG & p-n-p-α-D-galactoside | PGO | Yellow | Colorless | ONPG & p-n-p-α-D-galactoside | ≤10 |
| 4J | Urea | URE | Aqua/Blue | Yellow/Green | Urea | ≤50 |
| 2J | Esculin | ESC | Brown/Maroon | Clear/Tan | Esculin | ≤25 |
| 1J | Arginine | ARG | Purple | Yellow/Gray | Arginine | ≤200 |

Table 4
Quality Control Chart for BBL Crystal™ GP ID System
After 18–20 Hours Incubation from TSA II or Columbia Blood Agar

| Panel Location | Substrate | Code | <i>Streptococcus pyogenes</i> ATCC 19615 |
|----------------|----------------------------------|------|--|
| 4A | Fluorescent negative control | FCT | - |
| 2A | 4 MU-β-D-glucoside | FGC | - |
| 1A | L-valine-AMC | FVA | + |
| 4B | L-phenylalanine-AMC | FPH | + |
| 2B | 4MU-α-D-glucoside | FGS | + |
| 1B | L-pyrogutamic acid -AMC | FPY | + |
| 4C | L-tryptophan-AMC | FTR | + |
| 2C | L-arginine-AMC | FAR | + |
| 1C | 4MU-N-acetyl-β-D-glucosaminide | FGA | - |
| 4D | 4MU-phosphate | FHO | + |
| 2D | 4MU-β-D-glucuronide | FGN | - |
| 1D | L-isoleucine-AMC | FIS | + |
| 4E | Trehalose | FRE | + |
| 2E | Lactose | LAC | + |
| 1E | Methyl-α & β-glucoside | MAB | + |
| 4F | Sucrose | SUC | + |
| 2F | Mannitol | MNT | - |
| 1F | Maltotriose | MTT | + |
| 4G | Arabinose | ARA | - |
| 2G | Glycerol | GLR | + |
| 1G | Fructose | FRU | + |
| 4H | p-n-p-β-D-glucoside | BGL | + |
| 2H | p-n-p-β-D-cellobioside | PCE | - |
| 1H | Proline & Leucine-p-nitroanilide | PLN | - |
| 4I | p-n-p-phosphate | PHO | - |
| 2I | p-n-p-α-D-maltoside | PAM | + |
| 1I | ONPG & p-n-p-α-D-galactoside | PGO | -* |
| 4J | Urea | URE | - |
| 2J | Esculin | ESC | - |
| 1J | Arginine | ARG | + |

* = variable when tested from Columbia Blood Agar

Table 5
Additional Quality Control Strains for BBL Crystal™ GP ID System
After 18–20 Hours Incubation from TSA II or Columbia Blood Agar

| Panel Location | Substrate | Code | <i>Staphylococcus epidermidis</i> ATCC 12228 | <i>Bacillus brevis</i> ATCC 8246 | <i>Enterococcus faecalis</i> ATCC 19433 | <i>Staphylococcus xyloso</i> ATCC 35033 |
|----------------|----------------------------------|------|--|----------------------------------|---|---|
| 4A | Fluorescent negative control | FCT | - | - | - | - |
| 2A | 4MU-β-D-glucoside | FGC | - | + | + | - |
| 1A | L-valine-AMC | FVA | - | + | - | - |
| 4B | L-phenylalanine-AMC | FPH | - | + | + | - |
| 2B | 4MU-α-D-glucoside | FGS | -* | + | + | - |
| 1B | L-pyrogutamic acid-AMC | FPY | - | + | + | + |
| 4C | L-tryptophan-AMC | FTR | - | + | + | + |
| 2C | L-arginine-AMC | FAR | + | + | - | - |
| 1C | 4MU-N-acetyl-β-D-glucosaminide | FGA | - | + | + | - |
| 4D | 4MU-phosphate | FHO | + | + | + | + |
| 2D | 4MU-β-D-glucuronide | FGN | - | - | - | + |
| 1D | L-isoleucine-AMC | FIS | - | + | - | - |
| 4E | Trehalose | TRE | - | - | + | + |
| 2E | Lactose | LAC | + | - | + | + |
| 1E | Methyl-α & β-glucoside | MAB | - | - | + | + |
| 4F | Sucrose | SUC | + | - | + | + |
| 2F | Mannitol | MNT | - | - | + | + |
| 1F | Maltotriose | MTT | + | - | + | -* |
| 4G | Arabinose | ARA | - | - | - | + |
| 2G | Glycerol | GLR | + | - | + | + |
| 1G | Fructose | FRU | + | - | + | + |
| 4H | p-n-p-β-D-glucoside | BGL | - | + | + | + |
| 2H | p-n-p-β-D-cellobioside | PCE | - | - | + | - |
| 1H | Proline & Leucine-p-nitroanilide | PLN | + | + | - | - |
| 4I | p-n-p-phosphate | PHO | + | + | + | + |
| 2I | p-n-p-α-D-maltoside | PAM | -* | + | + | -* |
| 1I | ONPG & p-n-p-α-D-galactoside | PGO | + | - | - | + |
| 4J | Urea | URE | + | + | + | + |
| 2J | Esculin | ESC | - | + | + | - |
| 1J | Arginine | ARG | + | + | + | + |

* = variable when tested from Columbia Blood Agar

Table 6

Expected Reactions for Species Most Frequently Encountered in BBL Crystal™ GP ID System Clinical Trials

| Organism | FCT | FGC | FVA | FPH | FGS | FPY | FTR | FAR | FGA | FHO | FGN | FIS | TRE | LAC | MAB | SUC | MNT | MITT | ARA | GLR | FRU | BGL | PCE | PLN | PHO | PAM | PGO | URE | ESC | ARO |
|------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| <i>E. faecalis</i> | - | + | - | + | + | + | + | - | + | - | - | - | + | V | + | (+) | + | + | V | + | + | + | + | - | V | + | - | (-) | + | + |
| <i>E. faecium</i> | - | + | - | + | (-) | + | + | - | + | - | - | - | + | V | + | (+) | + | + | V | + | + | + | + | - | (-) | + | (+) | - | + | + |
| <i>S. aureus</i> | - | - | - | - | - | (-) | V | + | - | + | - | - | (+) | V | (+) | + | + | + | + | + | + | (+) | - | - | + | V | - | - | - | (+) |
| <i>S. capitis</i> | - | - | - | - | - | - | V | - | V | (-) | - | - | - | - | - | - | V | - | - | + | (+) | - | - | - | V | - | - | - | - | (+) |
| <i>S. epidermidis</i> | - | - | - | - | - | - | - | (-) | - | + | - | - | - | + | - | + | - | + | + | + | + | (-) | - | V | (+) | V | (-) | + | - | V |
| <i>S. haemolyticus</i> | - | - | - | - | - | + | - | (-) | V | - | (-) | + | (+) | V | (-) | + | V | + | + | + | (+) | V | - | - | V | V | (-) | - | - | V |
| <i>S. hominis</i> | - | - | - | - | - | - | - | V | - | - | - | - | V | V | - | V | - | (+) | - | + | + | (-) | - | V | V | V | (-) | + | - | - |
| <i>S. agalactiae</i> | - | - | V | + | (+) | - | + | + | - | + | V | V | + | V | + | + | V | + | - | V | + | (+) | - | V | + | - | - | - | - | V |
| <i>S. bovis</i> | - | + | + | + | + | - | + | V | V | - | V | + | (+) | + | + | + | V | + | - | - | + | + | + | + | (+) | V | - | + | - | + |
| <i>S. pneumoniae</i> | - | V | + | + | + | - | + | + | + | - | + | + | - | - | - | - | - | - | - | - | - | V | V | (+) | - | V | + | - | - | (-) |
| <i>S. pyogenes</i> | - | - | + | + | V | + | + | + | + | - | + | (-) | + | + | + | + | + | + | + | (+) | + | V | - | (+) | + | (-) | - | - | V | V |

KEY: + = 90% positive; (+) = 75-89% positive; V = 26-74% positive; (-) = 11-25% positive; - = 10% positive.

Table 7

Accuracy of Identification for Species Most Frequently Encountered in BBL Crystal™ GP ID System Clinical Trial

| Organism | Number Tested | BBL Crystal Correct ID | BBL Crystal Correct W/Supplemental Tests | Total Correct |
|---|---------------|------------------------|--|---------------|
| <i>Corynebacterium</i> species | 29 | 29 | 0 | 29 |
| <i>Enterococcus casseliflavus/gallinarum</i> | 14 | 0 | 14 ¹ | 14 |
| <i>Enterococcus faecalis</i> | 78 | 78 | 0 | 78 |
| <i>Enterococcus faecium</i> | 33 | 30 | 3 | 33 |
| <i>Micrococcus</i> species | 10 | 10 | 0 | 10 |
| <i>Staphylococcus aureus</i> | 88 | 85 | 3 | 88 |
| <i>Staphylococcus capitis</i> | 13 | 13 | 0 | 13 |
| <i>Staphylococcus epidermidis</i> | 87 | 87 | 0 | 87 |
| <i>Staphylococcus haemolyticus</i> | 23 | 23 | 0 | 23 |
| <i>Staphylococcus hominis</i> | 17 | 10 | 1 | 11 |
| <i>Streptococcus agalactiae</i> | 54 | 49 | 2 | 51 |
| <i>Streptococcus bovis</i> | 10 | 8 | 1 | 9 |
| <i>Streptococcus mitteri</i> group | 20 | 18 | 2 | 20 |
| <i>Streptococcus mitis</i> group ² | 23 | 8 | 1 | 9 |
| <i>Streptococcus pneumoniae</i> | 54 | 45 | 8 | 53 |
| <i>Streptococcus pyogenes</i> | 50 | 49 | 0 | 49 |
| Other * | 132 | 81 | 10 | 91 |
| Grand Total | 735 | 623 | 45 | 668 |

Key: * = This category comprises all isolates where less than 10 were encountered in clinical trials.
 1 = Colony pigmentation is the sole supplemental test required to obtain correct identification.
 2 = As follow-up to this group's accuracy results, remedial actions were subsequently implemented to improve performance.



Manufacturer / Výrobce / Producent / Fabrikant / Tootja / Valmistaja / Fabricant /
Herstellere / Κατασκευαστής / Gyártó / Ditta produttrice / Gamintojas / Producent /
Fabricante / Výrobca / Tillverkare



Use by / Spotřebujte do / Anvendes før / Houdbaar tot / Kasutada enne /
Viimeinkäyttöpäivä / A utiliser avant / Verwendbar bis / Ημερομηνία λήξης /
Felhasználhatóság dátuma / Usare entro / Naudokite iki / Brukes før / Stosować do /
Utilizar em / Použite do / Usar antes de / Använd före /
YYYY-MM-DD / YYYY-MM (MM = end of month) /
RRRR-MM-DD / RRRR-MM (MM = konec měsíce) /
AAAA-MM-DD / AAAA-MM (MM = slutning af måned) /
JJJJ-MM-DD / JJJJ-MM (MM = einde maand) /
AAAA-KK-PP / AAAA-KK (KK = kuu lõpp) /
VVVV-KK-PP / VVVV-KK (kuukauden loppuun mennessä) /
AAAA-MM-JJ / AAAA-MM (MM = fin du mois) /
JJJJ-MM-TT / JJJJ-MM (MM = Monatsende) /
EEEE-MM-HH / EEEE-MM (MM = τέλος του μήνα) /
EEEE-HH-NN / EEEE-HH (HH = hónap utolsó napja) /
AAAA-MM-GG / AAAA-MM (MM = fine mese) /
MMMM-MM-DD / MMMM-MM (MM = mēnesio pabaiga) /
AAAA-MM-DD / AAAA-MM (MM = sluttet av måneden) /
RRRR-MM-DD / RRRR-MM (MM = koniec miesiąca) /
AAAA-MM-DD / AAAA-MM (MM = fim do mês) /
RRRR-MM-DD / RRRR-MM (MM = koniec mesiaca) /
aaaa-mm-dd / aaaa-mm (mm = fin del mes) /
AAAA-MM-DD / AAAA-MM (MM = slutet på månaden)



Catalog number / Katalogové číslo / Katalognummer / Catalogusnummer / Kataloogi
number / Tuotenumero / Numéro catalogue / Bestellnummer / Αριθμός καταλόγου /
Katalógusszám / Numero di catalogo / Katalogo numeris / Numer katalogowy / Número
do catálogo / Katalógové číslo / Número de catálogo



Authorized Representative in the European Community / Autorizovaný zástupce pro
Evropskou unii / Autoriseret repræsentant i EU / Erkend vertegenwoordiger in de
Europese Unie / Volitatud esindaja Euroopa Nõukogus / Valtuutettu edustaja Euroopan
yhteisössä / Représentant agréé pour la C.E.E. / Autorisierte EG-Vertretung /
Εξουσιοδοτημένος αντιπρόσωπος στην Ευρωπαϊκή Κοινότητα / Hivatalos képviselő az
Európai Unióban / Rappresentante autorizzato nella Comunità europea / Įgaliojasis
atstovas Europos Bendrijoje / Autorisert representant i EU / Autoryzowane
przedstawicielstwo w Unii Europejskiej / Representante autorizado na União Europeia /
Autorizovaný zástupca v Európskom spoločenstve / Representante autorizado en la
Comunidad Europea / Auktoriserad representant i EU



In Vitro Diagnostic Medical Device / Lékařské zařízení určené pro diagnostiku in vitro / In
vitro diagnostisk medicinsk anordning / Medisch hulpmiddel voor in vitro diagnose / In
vitro diagnostika meditsiinaparatuur / Lääkinnällinen in vitro -diagnostikkalaitte /
Dispositif médical de diagnostic in vitro / Medizinisches In-vitro-Diagnostikum / In vitro
διαγνωστική ιατρική συσκευή / In vitro diagnosztikai orvosi eszköz / Dispositivo medico
diagnostico in vitro. / In vitro diagnostikos prietaisas / In vitro diagnostisk medisinsk
utstyr / Urządzenie medyczne do diagnostyki in vitro / Dispositivo médico para
diagnóstico in vitro / Medicínska pomôcka na diagnostiku in vitro / Dispositivo médico de
diagnóstico in vitro / Medicinsk anordning för in vitro-diagnostik



Temperature limitation / Teplotní omezení / Temperaturbegrænsning /
Temperatuurlimiet / Temperatuuri piirang / Lämpötilarajoitus / Température limite /
Zulässiger Temperaturbereich / Όριο θερμοκρασίας / Hőmérsékleti határ /
Temperatura limite / Laimymo temperatūra / Temperaturbegrænsning / Ograniczenie
temperatury / Limitação da temperatura / Ochraničenie teploty / Limitación de
temperatura / Temperaturbegrænsning



Batch Code (Lot) / Kód (číslo) šarže / Batch kode (Lot) / Chargennummer (lot) / Partii kood /
Erakoodi (LOT) / Code de lot (Lot) / Chargencode (Chargenbezeichnung) / Κωδικός
παρτίδας (Παρτίδα) / Tétel száma (Lot) / Codice del lotto (partita) / Partijos numeris (Lot) /
Batch-kode (Serie) / Kod partii (seria) / Código do lote (Lote) / Kód série (šarža) / Código
de lote (Lote) / Satskod (parti)



Consult Instructions for Use / Prostudujte pokyny k použití / Læs brugsanvisningen /
Raadpleeg gebruiksaanwijzing / Lugeda kasutusjuhendit / Tarkista käyttöohjeista /
Consulter la notice d'emploi / Gebrauchsanweisung beachten / Συμβουλευτείτε τις
οδηγίες χρήσης / Olvassa el a használati utasítást / Consultare le istruzioni per l'uso /
Skaitykite naudojimo instrukcijas / Se i bruksanvisningen / Zobacz instrukcja użytkowania /
Consulte as instruções de utilização / Pozri Pokyny na používanie / Consultar las
instrucciones de uso / Se bruksanvisningen